Nodul Tiroid

01Pathophysiology

Thyroid nodules represent focal areas of abnormal thyroid cell growth within an otherwise normal gland. The majority arise from clonal expansion of follicular epithelial cells, producing benign adenomas or colloid nodules. The fundamental question on any exam vignette is not "what is this nodule" but rather "is this nodule malignant, and how do I determine that systematically?"

The thyroid gland concentrates iodine and synthesizes T3/T4 under TSH stimulation. When a nodule is autonomously functioning, it produces thyroid hormone independent of TSH, which suppresses TSH through negative feedback. This is the rationale behind checking TSH first: a suppressed TSH suggests the nodule is "hot" (functioning), and hot nodules are almost never malignant. The next step in that scenario is a radionuclide scan (I-123 scintigraphy) to confirm autonomous function. If the nodule is hot, FNA is not needed.

Conversely, a normal or elevated TSH means the nodule is not autonomously functioning, and malignancy must be excluded. This is where ultrasound characterization and FNA biopsy become central. The pathophysiology of thyroid malignancy varies by type: papillary carcinoma (the most common, ~80%) spreads via lymphatics and is associated with radiation exposure and RET/PTC rearrangements. Follicular carcinoma invades through the capsule and spreads hematogenously to bone and lung. Medullary carcinoma arises from parafollicular C cells (not follicular epithelium), secretes calcitonin, and is associated with MEN2A/2B and RET proto-oncogene mutations. Anaplastic carcinoma is a rapidly growing undifferentiated tumor in elderly patients with an extremely poor prognosis.

The reason compressive symptoms like hoarseness are alarming is that the recurrent laryngeal nerve runs immediately posterior to the thyroid. A nodule causing vocal cord paralysis implies local invasion, which is a hallmark of aggressive malignancy rather than benign growth.

02Classification and Clinical Manifestation

Ultrasound Pattern Classification (ATA Risk Stratification)

The ATA guidelines classify nodules by their sonographic appearance to determine which nodules require FNA and at what size threshold.

Bethesda System for Reporting Thyroid Cytopathology

Clinical Features Suggesting Malignancy

03Diagnostic Workup

The ATA algorithm begins with TSH. This is the single most important first step, and it is the most commonly tested decision point. If TSH is low (subnormal), the algorithm directs you to a radionuclide thyroid scan before FNA. A hot nodule on scintigraphy is almost certainly benign (toxic adenoma) and does not require biopsy. The management shifts to treating hyperthyroidism. If the nodule is "cold" (non-functioning) or "warm" (indeterminate) on the scan, proceed to ultrasound-guided FNA.

If TSH is normal or elevated, skip the radionuclide scan entirely and go directly to thyroid ultrasound. The ultrasound serves two purposes: it risk-stratifies the nodule using the ATA sonographic patterns described above, and it determines whether the nodule meets the size threshold for FNA. A common exam trap is ordering FNA on every nodule regardless of size or ultrasound pattern. The ATA guidelines are clear that purely cystic nodules do not need FNA, and very low suspicion nodules are not biopsied unless they exceed 2 cm.

FNA cytology is interpreted through the Bethesda system. Bethesda II (benign) is followed with serial ultrasound. Bethesda VI (malignant) goes to surgery. The diagnostically challenging categories are Bethesda III and IV (indeterminate cytology), where molecular testing plays an increasingly tested role. Molecular tests like Afirma Gene Expression Classifier act as a "rule-out" test (high negative predictive value), helping to avoid unnecessary surgery for benign nodules with indeterminate cytology.

One critical nuance: follicular carcinoma cannot be diagnosed on FNA alone. FNA shows follicular cells but cannot assess capsular or vascular invasion, which is the defining feature of follicular carcinoma versus follicular adenoma. This is why Bethesda IV requires diagnostic lobectomy for definitive histopathologic evaluation. This distinction between cytology and histology is a heavily tested concept.

04Management and Treatment

Acute management in thyroid nodules is rarely about emergencies. The exception is anaplastic carcinoma presenting with rapid airway compromise, which may require urgent tracheostomy or debulking.

For differentiated thyroid cancers (papillary and follicular), post-surgical management centers on two pillars. First, radioactive iodine (I-131) remnant ablation destroys residual thyroid tissue and micrometastases. This is not given to every patient; ATA guidelines reserve it for intermediate- and high-risk patients (tumor >4 cm, gross extrathyroidal extension, distant metastases). Low-risk patients (intrathyroidal papillary carcinoma <4 cm without aggressive histology or nodal disease) can be observed without I-131.

Second, levothyroxine (T4) suppression therapy is started post-thyroidectomy at a dose that lowers TSH below the normal range. The rationale is that TSH stimulates thyroid follicular cells, so suppressing TSH reduces the growth stimulus on any residual cancer cells. The degree of suppression is calibrated to risk: high-risk patients target TSH <0.1 mU/L, while low-risk patients with excellent response to treatment can eventually allow TSH to normalize (0.5-2.0 mU/L).

Serum thyroglobulin serves as the tumor marker during long-term surveillance of differentiated thyroid cancer. A rising thyroglobulin after thyroidectomy and I-131 ablation suggests recurrent or persistent disease. Notably, anti-thyroglobulin antibodies can interfere with the assay, producing falsely low values.

For medullary thyroid carcinoma, the key management distinction is that I-131 is useless because C cells lack the sodium-iodide symporter and do not concentrate iodine. Total thyroidectomy with central compartment lymph node dissection is the standard surgical approach. RET mutation testing should be performed in all patients, and if positive, first-degree relatives must be screened.

During pregnancy, thyroid nodule evaluation can proceed with ultrasound and FNA (both safe). Radionuclide scanning is absolutely contraindicated. If FNA reveals malignancy, surgery can be performed in the second trimester if needed, or deferred to postpartum for low-risk differentiated cancers.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common mistake students make with thyroid nodule questions is skipping TSH and going directly to FNA or ultrasound. The ATA algorithm is unambiguous: TSH is always the first test. A low TSH fundamentally changes the diagnostic pathway because it triggers a radionuclide scan rather than a biopsy. If a vignette describes a patient with a thyroid nodule and includes symptoms of hyperthyroidism (weight loss, tremor, palpitations, heat intolerance), the answer is almost never "FNA" as the next step.

Another frequently tested trap involves nodule size versus ultrasound pattern. Students reflexively want to biopsy every nodule larger than 1 cm. The ATA guidelines make it clear that the decision to perform FNA depends on both sonographic pattern and size. A 1.3 cm spongiform nodule (very low suspicion) does not meet the 2 cm threshold for FNA and should be observed. Conversely, a 1.0 cm solid hypoechoic nodule with microcalcifications (high suspicion) absolutely requires biopsy.

A third trap is the question stem that presents Bethesda III or IV cytology and asks for the next step. The wrong answer is to repeat the same FNA indefinitely or to jump straight to total thyroidectomy. The tested concept is that molecular testing or diagnostic lobectomy is the appropriate next step for indeterminate cytology. Total thyroidectomy is reserved for confirmed malignancy or high clinical suspicion.

Remember that follicular carcinoma cannot be diagnosed by FNA. Any vignette describing a "follicular lesion" on cytology followed by a question about diagnosis is testing whether you know that only histology (via lobectomy) can distinguish follicular adenoma from carcinoma by demonstrating capsular or vascular invasion.

Finally, for medullary thyroid carcinoma, the pearl is that calcitonin is the tumor marker, not thyroglobulin, and radioactive iodine has no role. If a vignette mentions a thyroid nodule with elevated calcitonin or a family history of pheochromocytoma and hyperparathyroidism (MEN2A), the test-writer is asking you to recognize medullary carcinoma and order RET mutation analysis, not to follow the standard follicular cell algorithm.